natgillin/translations-raw huggingface dataset:
Conversely, if a woman on somatropin discontinues oral oestrogen therapy, the dose of somatropin may need to be reduced to avoid excess of growth hormone and/or side effects (see section 4.5). 
Nasprotno, če ženska, ki se zdravi s somatropinom, preneha z zdravljenjem s peroralnimi estrogeni, bo odmerek somatropina morda treba zmanjšati, da se prepreči presežek rastnega hormona in/ali pojav neželenih učinkov (glejte poglavje 4.5).
The maintenance dose in these patients seldom exceeds 0.5 mg per day. 
Vzdrževalni odmerek pri teh bolnikih redko presega 0,5 mg na dan.
• If you have raised intracranial pressure (which causes symptoms, such as strong headache, visual disturbances or vomiting) you should inform your doctor about it. 
• Če imate zvišan intrakranialni tlak (ki povzroča simptome, kot so močan glavobol, motnje vida ali bruhanje) to sporočite svojemu zdravniku.
It is also natural to have a higher level of growth hormone at night. 
Med spanjem so višje ravni rastnega hormona naravne.
The powder is white and the solvent is a clear, colourless solution. 
Prašek je bel, vehikel pa je bistra, brezbarvna raztopina.
In patients with a high likelihood for persistent GHD, i.e. a congenital cause or GHD secondary to a hypothalamic-pituitary disease or insult, an insulin-like growth factor-I (IGF-I) SDS < -2 off growth hormone treatment for at least 4 weeks should be considered sufficient evidence of profound GHD. 
Pri bolnikih, pri katerih je možnost persistentnega PRH velika, tj. prirojeni vzrok ali PRH zaradi bolezni ali insultu hipofize/hipotalamusa, je SDS insulinu podobnega rastnega faktorja-I (IGF-I) < -2 po zdravljenju z rastnim hormonom, ki je trajalo vsaj 4 tedne, zadostni znak velikega PRH.
Patients with childhood onset GHD should be re-evaluated for growth hormone secretory capacity after completion of longitudinal growth. 
Pri bolnikih z začetkom PRH v otroštvu je treba ponovno oceniti zmožnost izločanja rastnega hormona po zaključeni longitudinalni rasti.
A. MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE 
A. IZDELOVALEC BIOLOŠKE ZDRAVILNE UČINKOVIN IN IZDELOVALEC, ODGOVOREN ZA SPROŠČANJE SERIJ
In patients with endocrine disorders, including growth hormone deficiency, slipped epiphyses of the hip may occur more frequently than in the general population. 
Pri bolnikih z motnjami pri delovanju žlez z notranjim izločanjem, tudi s pomanjkanjem rastnega hormona, lahko pogosteje kot pri splošni populaciji zdrsne epifiza stegnenične glavice.
To avoid this, use a slightly different place for your injection each time. 
To preprečite tako, da si zdravilo vsakič injicirate na nekoliko drugo mesto.
• treat persons with pronounced growth hormone deficiency. 
• zdravljenje oseb z izrazitim pomanjkanjem rastnega hormona.
• After reconstitution, from a microbiological point of view, the product should be used immediately. 
• Po pripravi raztopine je zaradi mikrobioloških razlogov priporočena takojšnja uporaba zdravila.
After reconstitution, from a microbiological point of view, an immediate use is recommended. 
Po pripravi raztopine je zaradi mikrobioloških razlogov priporočena takojšnja uporaba zdravila.
Slipped capital femoral epiphysis occurs more frequently in case of endocrine disorders and Legg-Calvé-Perthes is more frequent in case of short stature. 
Zdrs epifize glavice stegnenice se pojavi pogosteje v primeru endokrinih motenj, Legg-Calvé-Perthesova bolezen pa je pogostejša pri manjši rasti.
Omnitrope (MAH: Sandoz), Zomacton and associated names (MAH: Ferring), Norditropin and associated names (MAH: Novo Nordisk), Genotropin and associated names (MAH: Pfizer) 
Omnitrope (imetnik dovoljenja za promet z zdravilom: Sandoz), Zomacton in povezana imena (imetnik dovoljenja za promet z zdravilom: Ferring), Norditropin in povezana imena (imetnik dovoljenja za promet z zdravilom: Novo Nordisk), Genotropin in povezana imena (imetnik dovoljenja za promet z zdravilom: Pfizer)
- The residual solution, vials, and injection materials intended for single use must be discarded. 
- Ostanke raztopine, vial in pribor za injiciranje, namenjen enkratni uporabi, morate zavreči.
Omnitrope is intended for subcutaneous use. 
Zdravilo Omnitrope je namenjeno za subkutano uporabo.
Paediatric population The posology and administration schedule should be individualised. 
Pediatrična populacija Odmerjanje in shema uporabe morata biti prilagojeni posamezniku.
Your other hand will be free to move the plunger. 
Z drugo roko boste lahko premikali bat.
Before initiation of treatment with somatropin patients with PWS should be evaluated for upper airway obstruction, sleep apnoea or respiratory infections should be assessed. 
Pred začetkom zdravljenja s somatropinom je treba pri bolnikih s PWS preveriti, ali imajo obstrukcijo zgornjega dela dihal in oceniti apnejo v spanju ali okužbo dihal.
• If you experience worsening abdominal pain you should inform your doctor. 
• Če se vam pojavijo bolečine v trebuhu, ki postajajo čedalje hujše, morate obvestiti zdravnika.
Visceral adipose tissue is particularly responsive to somatropin. 
Visceralno maščobno tkivo se na somatropin posebno rado odziva.
Pack sizes of 1, 5 or 10. 
Velikosti pakiranj po 1, 5 ali 10.
Adults with growth hormone deficiency: 
Odrasli s pomanjkanjem rastnega hormona:
Other medicines and Omnitrope 
Druga zdravila in zdravilo Omnitrope
Somatropin is a potent metabolic hormone of importance for the metabolism of lipids, carbohydrates and proteins. 
Somatropin je učinkovit presnovni hormon, ki je pomemben za presnovo maščob, ogljikovih hidratov in beljakovin.
If blood comes into the syringe, the needle has entered a blood vessel. 
Če priteka v injekcijsko brizgo kri, je igla zadela v žilo.
In SGA children/adolescents it is recommended to measure fasting insulin and blood glucose before start of treatment and annually thereafter. 
Pri otrocih/mladostnikih, ki so MGS, se priporoča merjenje vrednosti insulina in sladkorja v krvi na tešče pred začetkom zdravljenja in nato enkrat na leto.
‡ Clinical significance is unknown 
‡ Klinični pomen ni znan.
Chronic renal insufficiency 
Kronična ledvična insuficienca
• Stiffness in the arms and legs, muscle pain 
• togost rok in nog, bolečine mišic
If your growth hormone deficiency starts during adult life you should start with 0.15-0.3 mg per day. 
Če se pomanjkanje rastnega hormona pojavi v odrasli dobi, začnite z 0,15-0,3 mg na dan.
In addition to enhanced lipolysis, somatropin decreases the uptake of triglycerides into body fat stores. 
Somatropin povečuje lipolizo in zmanjšuje vnos trigliceridov v maščobne zaloge telesa.
Type 2 diabetes mellitus 
Presnovne in prehranske motnje diabetes mellitus tipa 2
In patients treated with somatropin, previously undiagnosed central (secondary) hypoadrenalism may be unmasked and glucocorticoid replacement may be required. 
Pri bolnikih, ki se zdravijo s somatropinom, se lahko izrazi predhodno prikriti centralni (sekundarni) hipoadrenalizem, ki lahko zahteva nadomestno zdravljenje z glukokortikoidi.
- Before you make an injection, clean your skin well with an alcohol swab. 
- Pred injiciranjem dobro očistite kožo z blazinico iz vate, namočeno v alkohol.
What Omnitrope looks like and contents of the pack 
Izgled zdravila Omnitrope in vsebina pakiranja
Excipient(s) with known effect: One ml contains 9 mg benzyl alcohol. 
Pomožne snovi z znanim učinkom: En ml vsebuje 9 mg benzilalkohola.
Experience in initiating treatment in SGA patients near onset of puberty is limited. 
Izkušenj z začetkom zdravljenja otrok z MGS, pri katerih se bo kmalu začela puberteta, je malo.
- Turn the vial and the syringe upside down in one hand. 
- Z eno roko obrnite vialo in injekcijsko brizgo navzdol tako, da oboje držite v eni roki.
This means that it is injected through a short injection needle into the fatty tissue just under your skin. 
To pomeni, da se daje s kratko injekcijsko iglo v maščevje tik pod kožo.
† Reported in growth hormone deficient children treated with somatropin, but the incidence appears to be similar to that in children without growth hormone deficiency. 
Poročila pri otrocih s pomanjkanjem rastnega hormona, zdravljenih s somatropinom, vendar pa kaže, da je pojavnost podobna pri otrocih brez pomanjkanja rastnega hormona.
*In general, these adverse effects are mild to moderate, arise within the first months of treatment, and subside spontaneously or with dose-reduction. 
*Na splošno so bili ti neželeni učinki blagi do zmerni in so se pojavili v prvih mesecih zdravljenja, nato pa so spontano ali z zmanjšanjem odmerka izzveneli.
After injecting - After injection, press the injection site with a small bandage or sterile gauze for several seconds. 
Po injiciranju - Po injiciranju pritiskajte na mesto injiciranja več sekund z majhnim povojem ali sterilno gazo.
• Temporary reddening, itchiness or pain at the injection site 
• začasna pordečitev, srbenje ali bolečina na mestu injiciranja
Higher doses may be needed if growth velocity is too low. 
Odmerek zdravila je lahko večji, če je rast prepočasna.
If the solution is cloudy or contains particulate matter, it should not be used. 
Če je raztopina motna ali vsebuje delce, je ne smete uporabiti.
Clinical trials in children with Turner syndrome 
Klinična preskušanja pri otrocih s Turnerjevim sindromom
Clinical trials in children with chronic renal insufficiency 
Klinična preskušanja pri otrocih s kronično ledvično insuficienco
Somatropin has been reported to reduce serum cortisol levels, possibly by affecting carrier proteins or by increased hepatic clearance. 
Poročali so, da somatropin niža ravni kortizola v serumu, morda z vplivom na nosilne beljakovine ali z zvečanjem jetrnega očistka.
Tumours must be inactive and you must have finished your anti-tumour treatment before you start your treatment with Omnitrope. 
Tumorji morajo biti neaktivni, preden začnete zdravljenje z zdravilom Omnitrope, pa morate zaključiti zdravljenje tumorja.
Data from an interaction study performed in growth hormone deficient adults suggests that somatropin administration may increase the clearance of compounds known to be metabolised by cytochrome P450 isoenzymes. 
Podatki iz preskušanja o medsebojnem delovanju zdravil, v kateri so sodelovali odrasli s pomanjkanjem rastnega hormona, kažejo, da somatropin lahko zveča očistek učinkovin, za katere je znano, da se presnavljajo s pomočjo izoencimov citokroma P450.
What Omnitrope is and what it is used for What you need to know before you use Omnitrope How to use Omnitrope 
Kaj je zdravilo Omnitrope in za kaj ga uporabljamo Kaj morate vedeti, preden boste uporabili zdravilo Omnitrope Kako uporabljati zdravilo Omnitrope Možni neželeni učinki
• Water retention (which shows as puffy fingers or swollen ankles) Common side effects (likely to occur in fewer than 1 in 10 patients) include: In children 
• zastajanje vode (kar se kaže kot nabrekli prsti ali otekli gležnji) Pogosti neželeni učinki (pojavijo se lahko pri največ 1 od 10 bolnikov) vključujejo: Pri otrocih
There have been no clinical studies conducted with somatropin containing products in breast-feeding women. 
Kliničnih študij s somatropinom, v katerih bi bile vključene ženske, ki dojijo, niso izvedli.
The top of the vials should be wiped with an antiseptic solution to prevent contamination of the contents. 
Zgornji del viale obrišite z antiseptično raztopino, da preprečite kontaminacijo vsebine.
If you have been treated with Omnitrope for growth hormone deficiency during childhood, your growth hormone status will be retested after completion of growth. 
Če ste se v otroštvu zdravili z zdravilom Omnitrope zaradi pomanjkanja rastnega hormona, se vaše stanje rastnega hormona ponovno preveri, ko prenehate rasti.
- the Omnitrope Pen , an injection device specifically developed for use with Omnitrope solution for injection (not supplied in the pack; see Instructions for Use provided with the Omnitrope Pen). 
- injekcijski peresnik SurePal, pripravo za injiciranje, narejeno posebej za uporabo raztopine za injiciranje zdravila Omnitrope (ki je ni v ovojnini; glejte Navodila za uporabo, priložena napravi SurePal).
Solution for injection in a cartridge for SurePal 5, SurePal 10, SurePal 15. 
Raztopina za injiciranje v vložku za injekcijski peresnik SurePal 5, Surepal 10, Surepal 15.
After the needle is in, remove the hand used to pinch the skin and use it to hold the syringe barrel. 
Ko je igla v koži, odmaknite roko, s katero ste stiskali kožo, in z njo primite valj brizge.
Powder and solvent for solution for injection (powder in a vial (1.3 mg), solvent in a vial (1 ml)). 
Prašek in vehikel za raztopino za injiciranje (prašek v viali (1,3 mg), vehikel v viali (1 ml)).
Musculoskeletal stiffness* 
mišišnoskeletna okorelost*
- Prader-Willi syndrome (PWS), for improvement of growth and body composition. 
- Prader-Willijev sindrom (PWS), za izboljšanje rasti in sestave telesa; diagnoza PWS se postavi na podlagi ustreznih genetskih preiskav.
Slipped capital femoral epiphysis and Legg-Calvé-Perthes disease may be considered by your doctor if discomfort or pain in the hip or knee is experienced whilst being treated with Omnitrope. 
Zdravnik lahko pomisli na zdrs epifize glavice stegnenice in Legg-Calvé-Perthesovo bolezen, če se med zdravljenjem z zdravilom Omnitrope pojavi nelagodje ali bolečina v kolku ali kolenu.
If you stop using Omnitrope 
Če ste prenehali uporabljati zdravilo Omnitrope
In short children/adolescents born SGA, other medical reasons or treatments that could explain growth disturbance should be ruled out before starting treatment. 
Pri otrocih/mladostnikih, ki so se za svojo gestacijsko starost rodili majhni (MGS), je treba pred začetkom zdravljenja izključiti druge zdravstvene težave ali vrste zdravljenja, ki bi lahko pojasnile motnjo pri rasti.
Long-term administration of somatropin to growth hormone deficient patients with osteopenia results in an increase in bone mineral content and density at weight-bearing sites. 
Dolgotrajna uporaba somatropina pri bolnikih z osteopenijo in pomanjkanjem rastnega hormona povzroči zvečanje mineralne gostote kosti ter gostote na mestih, ki nosijo telesno maso.
• If you are at risk of developing diabetes, your doctor will need to monitor your blood sugar level during therapy with somatropin. 
• Če obstaja tveganje, da se razvije sladkorna bolezen, bo moral zdravnik med zdravljenjem s somatropinom nadzirati vaše vrednosti sladkorja v krvi.
MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE 
IZDELOVALCI BIOLOŠKE ZDRAVILNE UČINKOVIN IN IZDELOVALEC, ODGOVOREN ZA SPROŠČANJE SERIJ
• Reddening, itchiness or pain at the injection site 
• pordečitev, srbenje ali bolečina na mestu injiciranja
Based on available literature, hypothalamic-pituitary-adrenal axis can be affected and needs to be re-assessed during growth hormone therapy in growth hormone deficient patients, who were previously not found to be deficient in this axis. 
Na podlagi razpoložljivih podatkov iz literature je delovanje osi hipotalamus-hipofiza-nadledvična žleza lahko prizadeto in ga je pri bolnikih s pomanjkanjem rastnega hormona, pri katerih pomanjkljivo delovanje te osi predhodno ni bilo odkrito, med zdravljenjem z rastnim hormonom treba znova ovrednotiti.
- Check for air bubbles in the syringe. 
- Preverite, da v brizgi ni zračnih mehurčkov.
The following instructions explain how to inject Omnitrope yourself. 
Navodila v nadaljevanju pojasnjujejo, kako si lahko sami injicirate zdravilo Omnitrope.
Reconstituting Omnitrope - Remove the protective cap from the vial. 
Priprava zdravila Omnitrope - Odstranite zaščitno zaporko z viale.
Clinical trials in children with Turner syndrome Table 2 
Klinična preskušanja pri otrocih s Turnerjevim sindromom Preglednica 2
Remove any air bubbles from the syringe. 
Iz brizge odstranite vse zračne mehurčke.
Flip off the plastic protective cap from the vial. 
Z viale odtrgajte plastično zaščitno zaporko.
In addition, patients treated with glucocorticoid replacement therapy for previously diagnosed hypoadrenalism may require an increase in their maintenance or stress doses, following initiation of somatropin treatment (see section 4.5). 
Pri bolnikih, ki zaradi predhodno ugotovljenega hipoadrenalizma že prejemajo nadomestno zdravljenje z glukokortikoidi, bo po uvedbi zdravljenja s somatropinom morda treba povečati vzdrževalni ali stresni odmerek glukokortikoidov (glejte poglavje 4.5).
Long-term treatment of children with growth disturbance due to born small for gestational age System Organ 
Dolgotrajno zdravljenje otrok z motnjami v rasti, ker so se rodili majhni za svojo gestacijsko starost
• If you are receiving treatment with thyroid hormones it may become necessary to adjust your thyroid hormone dose. 
• Če se zdravite s ščitničnim hormonom, bo morda treba prilagoditi odmerek ščitničnega hormona.
In patients above 60 years, therapy should start with a dose of 0.1 - 0.2 mg per day and should be slowly increased according to individual patient requirements. 
Pri bolnikih, starih več kot 60 let, se zdravljenje začne z odmerkom 0,1 - 0,2 mg na dan in se nato postopoma povečuje skladno z bolnikovimi individualnimi potrebami.
Dispose of the syringes safely in a closed container. 
Injekcijske brizge varno odložite v zaprto posodo, namenjeno zanje.
Their diagnosis should be considered in a child with a discomfort or pain in the hip or knee. 
Pri otrocih z nelagodjem ali bolečino v kolku ali kolenu je treba pomisliti na ti diagnozi.
Turn the vial upside down and using another sterile, disposable syringe of appropriate size (e.g. 1 ml syringe) and injection needle (e.g. 0.25 mm x 8 mm) withdraw a bit more than the dose needed back into the syringe. 
Zgornji del viale obrnite navzdol in s pomočjo druge sterilne injekcijske brizge za enkratno uporabo primerne velikosti (npr. 1-mililitrske brizge) ter injekcijske igle (npr. 0,25 mm x 8 mm) prečrpajte nekoliko večjo količino, kot je odmerek, ki ga potrebujete, nazaj v brizgo.
Chronic renal insufficiency Children/adolescents born small for gestational age (SGA) 
Motnje rasti pri majhnih otrocih/mladostnikih, ki so se za svojo gestacijsko starost rodili majhni (MGS)
- Hold the syringe with the needle in the vial pointing up and remove the syringe from the vial. 
- Brizgo z iglo držite v viali s konico navzgor in jo potegnite iz viale.
Intracranial tumours, in particular meningiomas, in patients treated with radiation to the head for their first neoplasm, were the most common of these second neoplasms. 
Najpogostejše sekundarne novotvorbe so bile intrakranialni tumorji, zlasti meningiomi, pri bolnikih, zdravljenih z obsevanjem glave zaradi prve novotvorbe.
Pack sizes of 1, 5 and 10. 
Velikosti pakiranja po 1, 5 in 10.
Even higher doses have been used. 
Uporabljajo se lahko tudi večji odmerki zdravila.
Intracranial tumours must be inactive and anti-tumour therapy must be completed prior to starting GH therapy. 
Intrakranialni tumorji morajo biti nedejavni, zdravljenje tumorja pa se mora končati pred začetkom zdravljenja z rastnim hormonom.
Medical treatment for your kidney should be continued. 
Zdravljenje ledvic naj se nadaljuje.
Patients with growth hormone deficiency are characterised by extracellular volume deficit. 
Za bolnike s pomanjkanjem rastnega hormona je značilen primanjkljaj zunajcelične prostornine.
If you forget to use Omnitrope 
Če ste pozabili vzeti zdravilo Omnitrope
Other adverse drug reactions 
Drugi neželeni učinki zdravila
Omnitrope 5 mg/1.5 ml solution for injection: One ml contains 9 mg benzyl alcohol. 
Omnitrope 5 mg/1,5 ml raztopina za injiciranje: En ml vsebuje 9 mg benzilalkohola.
Do not share your needles. 
Svojih igel ne dajajte drugim.
Use with oral oestrogen therapy 
Uporaba skupaj s peroralnim estrogenskim zdravljenjem
Children with Prader-Willi syndrome: 
Otroci s Prader-Willijevim sindromom:
In addition, patients already receiving glucocorticoid replacement therapy may need to have the dose of their replacement therapy adjusted, after somatropin treatment is initiated. 
Poleg tega pa bo pri bolnikih, ki se že zdravijo z nadomeščanjem glukokortikoidov, po uvedbi zdravljenja s somatropinom morda treba prilagoditi odmerek glukokortikoida pri nadomestnem zdravljenju.
The clinical significance of this is unknown. 
Klinični pomen tega dejstva ni znan.
- Gently swirl the reconstituted vial until the content is completely dissolved. 
- Pripravljeno vsebino viale narahlo vrtite, dokler se vsebina povsem ne raztopi.
Paraesthesia* Benign intracranial hypertension 
Bolezni živčevja parestezija* benigna intrakranialna hipertenzija
Taking into account the PRAC Assessment Report on the PSUR(s) for somatropin, the scientific conclusions of CHMP are as follows: 
Upoštevajoč poročilo Odbora za oceno tveganja na področju farmakovigilance (PRAC) o oceni rednih posodobljenih poročil o varnosti zdravila (PSUR) za somatropin je Odbor za zdravila za uporabo v humani medicini (CHMP) sprejel naslednje znanstvene zaključke: Vsa zdravila:
The injection should be given subcutaneously and the site varied to prevent lipoatrophy. 
Zdravilo se injicira subkutano, mesto injiciranja pa se spreminja in tako prepreči pojav lipoatrofije.
Therefore, in order to achieve an equivalent clinical and biochemical response compared to men dose adjustments may need to be considered by the prescriber in female patients. 
Pri bolnicah bo tako za dosego enakovrednega kliničnega in biokemičnega odziva kot pri moških odmerek morda treba prilagoditi.
Somatropin induces the retention of sodium, potassium and phosphorus. 
Somatropin povzroči zastajanje natrija, kalija in fosforja v telesu.
The very common and common side effects in adults may start within the first months of treatment and may either stop spontaneously or if your dose is reduced. 
Ti zelo pogosti in pogosti neželeni učinki pri odraslih se lahko začnejo prve mesece zdravljenja in izzvenijo spontano ali z zmanjšanjem odmerka.
Powder and solvent for solution for injection (powder in a vial (5 mg), solvent in a cartridge (1 ml)) Pack sizes of 1 and 5. 
Prašek in vehikel za raztopino za injiciranje (prašek v viali (5 mg) in vehikel v vložku (1 ml)) Velikosti pakiranja po 1 in 5.
The following is a general description of the administration process. 
V nadaljevanju je splošen opis uporabe zdravila.
1 vial of 5 mg powder 1 cartridge of 1 ml solvent 5 vials of 5 mg powder 5 cartridges of 1 ml solvent 
1 viala s 5 mg praška 1 vložek z 1 ml vehikla 5 vial s 5 mg praška 5 vložkov z 1 ml vehikla
Use only with Omnitrope Pen L. Read package leaflet before use. 
Uporabljajte samo z injekcijskim peresnikom Omnitrope Pen L. Pred uporabo preberite priloženo navodilo!
For guidance on dosing see adult section below. 
Glejte spodnje smernice za odmerjanje pri odraslih.
NAME OF THE MEDICINAL PRODUCT AND ROUTE OF ADMINISTRATION Solvent for Omnitrope (water for injections with 1.5% benzyl alcohol) Subcutaneous use. 
Vehikel za zdravilo Omnitrope (vode za injekcije z 1,5-odstotnim benzilalkoholom)subkutana uporaba
Slipped capital femoral epiphysis and Legg-Calvé-Perthes disease 
Zdrs epifize glavice stegnenice in Legg-Calvé-Perthesova bolezen
Based on available literature, higher doses of growth hormone are generally required during the initiation and maintenance phases of treatment in women with an intact hypothalamic-pituitarygonadal axis and on oral oestrogens. 
Na podlagi razpoložljivih podatkov iz literature so pri ženskah z intaktno osjo hipotalamus-hipofizaspolne žleze, ki se zdravijo s peroralnimi estrogeni, v začetni in vzdrževalni fazi zdravljenja na splošno potrebni večji odmerki rastnega hormona.
Measuring the dose of Omnitrope to be injected - Take the sterile, disposable syringe of appropriate size (e.g. 1 ml syringe) and injection needle (e.g. 0.25 mm x 8 mm). 
Določanje odmerka zdravila Omnitrope, ki ga je treba injicirati - Vzemite sterilno brizgo primerne velikosti za enkratno uporabo (npr. 1-mililitrsko) in injekcijsko iglo (npr. 0,25 mm x 8 mm).
The maintenance dose rarely exceeds 1.0 mg per day. 
Dnevni vzdrževalni odmerek redko preseže 1,0 mg na dan.
Use only with Omnitrope Pen 10. 
Uporabljajte samo z injekcijskim peresnikom Omnitrope Pen 10.
- The active substance of Omnitrope is somatropin. 
- Zdravilna učinkovina v zdravilu Omnitrope je somatropin.